Meyahealth
HomeGeneticsConditionMucolipidosis type IV
Back to Condition
Mucolipidosis type IV
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Mucolipidosis type IV

Mucolipidosis type IV is a rare, inherited lysosomal storage disorder characterized by delayed psychomotor development and progressive vision impairment that worsens over time.

Overview

Mucolipidosis type IV is an inherited disorder that primarily affects development and vision. The condition is classified into two forms based on severity: a severe form known as typical mucolipidosis type IV, and a milder form called atypical mucolipidosis type IV.

Symptoms & Types

The signs and symptoms of the condition vary depending on the specific form diagnosed:

Typical Mucolipidosis type IV

Approximately 95 percent of affected individuals have the severe, typical form. Key features include:

  • Psychomotor delay: Moderate to severe delay in mental and motor skills (such as sitting, standing, walking, grasping objects, and writing) that usually becomes apparent during the first year of life.
  • Neurological and motor issues: Intellectual disability, limited or absent speech, difficulty chewing and swallowing, weak muscle tone (hypotonia) that gradually turns into abnormal muscle stiffness (spasticity), and problems controlling hand movements. Most affected individuals are unable to walk independently, and about 15 percent experience worsening psychomotor problems over time.
  • Vision impairment: Vision may be normal at birth but worsens during the first decade of life. Affected individuals develop clouding of the clear covering of the eye (cornea) and progressive breakdown of the light-sensitive layer at the back of the eye (retina), leading to severe vision loss or blindness by their early teens.
  • Stomach and blood abnormalities: Impaired production of stomach acid (achlorhydria), which does not cause symptoms but results in unusually high levels of gastrin (a hormone regulating stomach acid production) in the blood. Affected individuals may also have low iron levels, potentially leading to a shortage of red blood cells.

People with the severe form usually survive to adulthood, though they may have a shortened lifespan.

Atypical Mucolipidosis type IV

About 5 percent of affected individuals have the mild, atypical form. Characteristics include:

  • Mild psychomotor delay, with some individuals developing the ability to walk.
  • Milder eye abnormalities compared to the severe form.
  • Potential presence of achlorhydria.

Frequency

Mucolipidosis type IV is estimated to occur in 1 in 40,000 people. Approximately 70 percent of those affected have Ashkenazi Jewish ancestry.

Causes & Genetic Factors

Mutations in the MCOLN1 gene cause mucolipidosis type IV. This gene provides instructions for making a protein called mucolipin-1, which is located in the membranes of lysosomes and endosomes (compartments within the cell that digest and recycle materials).

While its exact function is not fully understood, mucolipin-1 plays a role in the transport (trafficking) of fats (lipids) and proteins between lysosomes and endosomes. It appears to be important for the development and maintenance of the brain and retina, as well as the normal functioning of acid-producing cells in the stomach.

Most mutations in the MCOLN1 gene result in a nonfunctional protein or prevent any protein from being produced. This lack of functional mucolipin-1 impairs lipid and protein transport, causing these substances to build up inside lysosomes. Because of this accumulation, mucolipidosis type IV is classified as a lysosomal storage disorder. Two specific mutations in the MCOLN1 gene account for almost all cases of the condition in people of Ashkenazi Jewish ancestry.

Inheritance

This condition is inherited in an autosomal recessive pattern. This means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene but typically do not show signs and symptoms of the condition.

Other Names for This Condition

  • Ganglioside sialidase deficiency
  • ML4
  • MLIV
  • Sialolipidosis

Frequently Asked Questions

Parents should look for clouding of the cornea, redness, or a yellowish tint in the eye. Once a diagnosis is made, ophthalmology evaluations should occur every 3–6 months in the first two years and then at least annually, as corneal clouding and retinal degeneration progress over time. Early detection can guide interventions such as corneal transplantation or low‑vision support. How does the typical form of mucolipidosis type IV affect speech and swallowing, and what therapies can help?::Children often have limited speech, delayed language milestones, and difficulty chewing or swallowing due to hypotonia and muscle weakness. Speech and language therapy can improve articulation and communication strategies, while feeding therapy can teach safe swallowing techniques. In severe cases, a gastrostomy tube may be considered to ensure adequate nutrition and reduce aspiration risk. Are there specific dietary or nutritional strategies that can support growth in children with mucolipidosis type IV?::Because these children may have impaired gastric acid production, a high‑calorie, nutrient‑dense diet is recommended. Supplements such as vitamin B12, vitamin D, calcium, and omega‑3 fatty acids can support bone health and overall growth. Some families find that small, frequent meals and a high‑protein intake help maintain weight. Consultation with a dietitian experienced in lysosomal storage disorders is advised. What genetic counseling options are available for families with a history of mucolipidosis type IV?::Genetic counseling can clarify the autosomal‑recessive inheritance and estimate recurrence risk. Carrier testing for the specific mutation in the affected family can be performed on both parents. For future pregnancies, options include chorionic villus sampling (10–12 weeks), amniocentesis (15–20 weeks), or pre‑implantation genetic diagnosis with in‑vitro fertilization to select embryos that do not carry the mutation.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ